THE THERAPEUTIC POTENTIAL OF CANNABIDIOL IN ALZHEIMER'S DISEASE

Abstract

Alzheimer's disease (AD) is a chronic and progressive neurodegenerative condition that affects several body systems. It is a complex disease that does not yet have a fully defined and understood cause. There are drugs that can help slow down the progression and improve the symptoms of the disease, but there is currently no definitive cure. Cannabidiol, one of the compounds in the Cannabis sativa plant, has anti-inflammatory and neuroprotective properties and has emerged as a potential therapeutic agent for AD. This study aimed to analyze, through a literature review, the therapeutic potential of cannabidiol (CBD) in the management of cognitive, behavioral and neuroinflammatory symptoms associated with Alzheimer's disease (AD). Methodologically, a bibliographic review was carried out on the subject in the PubMed database, between the years 2023 and 2025. Cannabidiol has been shown to have a variety of beneficial effects in in vitro and in vivo models, and these findings support the compound's promising ability to counteract cognitive and memory impairments in AD. However, more research is needed to ensure its safety and efficacy.